Genotyping of the G1463A (Arg441His) TPH2 polymorphism in a geriatric population of patients with major depression Molecular Psychiatry (2006) 11, 799-800. doi:10.1038/sj.mp. 4001861 Tryptophan hydroxylase (TPH) is a rate-limiting enzyme in the biosynthesis of 5-HT with two isoforms. TPH1 is mainly expressed in peripheral tissues whereas TPH2 is preferentially expressed in the brain serotonergic neurons from the raphe nuclei. Therefore, molecular alterations of the TPH2 gene (chromosome 12q15) have been proposed as a candidate gene associated with many behavioral phenomena including mood disorders, suicide, personality traits and substance abuse.
Recently, Zhang et al. 1,2 identified a functional (G1463A) single-nucleotide polymorphism (SNP) in the TPH2 gene. This alteration results in substitution of a highly conserved arginine residue at position 441 by a histidine (Arg441His). They demonstrated that the levels of 5-HT were 80% lower in PC-12 cells expressing the Arg441His mutant, indicating a severe loss of the mutant's enzyme function to synthesize 5-HT. They also described nine subjects carrying this functional SNP in a cohort of 87 unipolar major depression patients, all over the age of 60 years and from multiple ethnic groups.
More recently, Blakely et al. 3 pointed out that several groups did not find the variant described by Zhang et al. 2 after studying nearly 5000 patients. [4] [5] [6] To add to this puzzle, DNA from the patients with the G1463A polymorphism were kindly made available by Dr Caron's lab to those groups who confirmed the presence of that SNP. However, these data suggest an association of the G1463A variant with severe depression that is refractory to conventional medication, necessitating electrical convulsive therapy (ECT). 2, 7 Moreover, the elderly nature of the cohort raises the possibility that these traits could be related to late onset depression.
Based on these findings, and considering that replication of genotyping data in populations with ethnically heterogeneous background is essential for the understanding of the importance of the initial report, we investigated exon 11 of the TPH2 gene in samples of patients from a Geriatric Reference Center in Belo Horizonte, Brazil. Our cohort comprised 102 patients (87 females, 15 males, age 62-94 years, the mean age at inclusion was 77.3 years), from many ethnic backgrounds, with the diagnosis of late onset major depression according to the Diagnostic and Statistical Manual-IV and the Geriatric Depression Scale, some of them with severe depression. We also analyzed environmental factors frequently related to depression diagnosis like death, socioeconomical problems, concurrent diseases, physical disabilities, caregiver stress and institutionalization. There were 57 subjects in our control group (34 females, 23 males, all 60 years-old or older, the mean age at inclusion was 67.9 years), without personal or familial history of psychiatric disorders. This study was approved by the local Ethics Committee and all subjects signed an informed consent. After DNA extraction (two independent extractions), exon 11 of the TPH2 gene was amplified by PCR (primers available on request) and directly sequenced (in duplicate, both forward and reverse directions) in an ABI 310 automatic sequencer. We did not find the A-allele (His441) in any of the 102 patients or in the controls. Therefore, our data support the notion that this rare TPH2 variant is also not a major determinant of genetic risk for depression in geriatric patients. The high frequency of the minor allele previously found in a geriatric sample 2 might be the result of population stratification. However, considering the failure to replicate their findings in a large independent sample (over 5000 subjects from different populations) [4] [5] [6] and the frequency of the observation of the His441 variant in the initial sample, including a few homozygotes, 2 possible technical artefacts, other than genotype readings cannot be ruled out. The aetiology of major depressive disorder (MDD) has been linked, variously, to brain monoaminergic neuronal dysfunction, alterations in monoamine receptor sensitivity and stress-induced activation of the hypothalamic-pituitary-adrenal axis. In an effort to unify these observations, Duman et al.
1 recently proposed the neurotrophic hypothesis of depression. Duman posits that vulnerability to depression induced by stress-induced activation of the HPA-axis and the therapeutic action of antidepressant treatments are both due to intracellular mechanisms that decrease or increase, respectively, neurotrophic factors necessary for the survival and function of particular neurons. 1 While most attention has focused on brain-derived neurotophic factor, in an elegant study, leptin was recently demonstrated to act as a neurotrophic factor in the mouse hypothalamus, rapidly influencing neuronal arborisation. 2 With this as a basis, and given that we have previously demonstrated leptin production by the brain in healthy subjects, 3, 4 we hypothesised that patients with MDD, controlled for gender, age and obesity, would exhibit a reduction in brain leptin production.
Twenty patients (8 males/12 females, aged 4573 years, body mass index (BMI) 2771) fulfilling the DSM-IV diagnostic criteria for MDD and 20 healthy subjects (10 males/10 females, aged 4072 years, BMI 2671) were recruited following local media advertisement. Patients with depression were either newly diagnosed or currently untreated after a recent relapse. Following initial telephone screening, patients were interviewed by a psychiatrist utilising a structured clinical interview (Mini International Neuropsychiatric Interview (MINI)). Hamilton Depression Scale (17 item) and Beck Depression Inventory (BDI-1) were used to monitor severity. Eligibility for entry was determined by HamD > 18, BDI > 18, positive for major depression on MINI and assessed as having a significant major depression as the primary illness on interview by a psychiatrist. Patients with comorbid panic or anxiety disorders were included in the study if the primary diagnosis was depression and any panic/anxiety was secondary to their depression. All participants had a general medical review and examination by a medical practitioner to exclude any previously undiagnosed medical conditions. Exclusion criteria included coexistent physical illness and comorbid psychotic disorders, eating disorders, mental retardation, high suicide risk, cluster borderline personality disorders and epilepsy. The research protocol conformed to the relevant guidelines of the National Health and Medical Research Council of Australia and was approved by the Alfred Hospital Ethics Review Committee. Written informed consent was obtained from each subject prior to the study. The process of consent, to which an honest, open, and explicit patient information sheet was central, preserved the autonomy of the participants. Healthy volunteers were paid a nominal amount of US$75 for their participation. Following the study patients with MDD were referred to a psychiatrist for clinical management.
Blood samples were obtained simultaneously from the right internal jugular vein and brachial artery using percutaneously placed catheters as previously described. 5 Data are expressed as mean7s.e.m. For comparing data between patients and healthy subjects, Student's t-test or the Mann-Whitney test were used as appropriate. P < 0.05 was considered as statistically significant.
Brain leptin mRNA expression was determined from biopsy material obtained at autopsy from 10 subjects (age: 4675; BMI: 2671) at the Victorian Institute of Forensic Medicine (VIFM). The informed consent of the donor's next-of-kin was obtained before the autopsy and the VIFM Ethics Review Committee
